Disinhibition of the Nucleus Accumbens Leads to Macro-Scale Hyperactivity Consisting of Micro-Scale Behavioral Segments Encoded by Striatal Activity.


Journal

The Journal of neuroscience : the official journal of the Society for Neuroscience
ISSN: 1529-2401
Titre abrégé: J Neurosci
Pays: United States
ID NLM: 8102140

Informations de publication

Date de publication:
24 07 2019
Historique:
received: 13 12 2018
revised: 14 05 2019
accepted: 16 05 2019
pubmed: 28 5 2019
medline: 18 6 2020
entrez: 26 5 2019
Statut: ppublish

Résumé

The striatum comprises of multiple functional territories involved with multilevel control of behavior. Disinhibition of different functional territories leads to territory-specific hyperkinetic and hyperbehavioral symptoms. The ventromedial striatum, including the nucleus accumbens (NAc) core, is typically associated with limbic input but was historically linked to high-level motor control. In this study, performed in female Long-Evans rats, we show that the NAc core directly controls motor behavior on multiple timescales. On the macro-scale, following NAc disinhibition, the animals manifested prolonged hyperactivity, expressed as excessive normal behavior, whereas on the micro-scale multiple behavior transitions occurred, generating short movement segments. The underlying striatal network displayed population-based local field potential transient deflections (LFP spikes) whose rate determined the magnitude of the hyperactivity and whose timing corresponded to unitary behavioral transition events. Individual striatal neurons preserved normal baseline activity and network interactions following the disinhibition, maintaining the normal encoding of behavioral primitives and forming a sparse link between the LFP spikes and single neuron activity. Disinhibition of this classically limbic territory leads to profound motor changes resembling hyperactivity and attention deficit. These behavioral and neuronal results highlight the direct interplay on multiple timescales between different striatal territories during normal and pathological conditions.

Identifiants

pubmed: 31126998
pii: JNEUROSCI.3120-18.2019
doi: 10.1523/JNEUROSCI.3120-18.2019
pmc: PMC6650982
doi:

Substances chimiques

GABA Antagonists 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

5897-5909

Informations de copyright

Copyright © 2019 the authors.

Références

J Pharmacol Exp Ther. 2000 Jan;292(1):406-14
pubmed: 10604977
Eur J Neurosci. 2000 Mar;12(3):1033-7
pubmed: 10762334
J Neural Transm. 1979;45(1):17-33
pubmed: 112217
J Neurosci Methods. 2001 May 30;107(1-2):1-13
pubmed: 11389936
Ann N Y Acad Sci. 2001 Jun;931:33-49
pubmed: 11462751
Eur J Pharmacol. 1975 May;32(1):87-92
pubmed: 1171020
Exp Brain Res. 2001 Nov;141(2):146-52
pubmed: 11713626
Pediatr Rev. 2003 Feb;24(2):39-51
pubmed: 12563038
Biol Psychiatry. 2003 May 15;53(10):871-8
pubmed: 12742674
Brain. 2004 Sep;127(Pt 9):2039-54
pubmed: 15292053
J Neurosci. 2004 Sep 8;24(36):7916-22
pubmed: 15356204
Trends Neurosci. 2006 Mar;29(3):175-82
pubmed: 16430974
Pharmacol Biochem Behav. 1991 Apr;38(4):829-35
pubmed: 1651518
Biol Psychiatry. 2007 Mar 1;61(5):720-4
pubmed: 16950228
Nat Neurosci. 2008 Jun;11(6):637-9
pubmed: 18488025
Neurosci Res. 1991 Feb;10(1):34-51
pubmed: 1851976
Am J Psychiatry. 2009 Jan;166(1):74-82
pubmed: 19015232
Cereb Cortex. 2009 Aug;19(8):1844-56
pubmed: 19068490
Brain. 2009 Aug;132(Pt 8):2125-38
pubmed: 19506070
Biol Psychiatry. 2009 Nov 15;66(10):972-7
pubmed: 19576573
Neuroscience. 1991;41(1):89-125
pubmed: 2057066
J Neurophysiol. 2010 Dec;104(6):3261-75
pubmed: 20592118
J Neurosci. 2011 Jan 26;31(4):1183-92
pubmed: 21273403
J Neurosci. 2011 Jun 15;31(24):8713-21
pubmed: 21677155
Pharmacol Biochem Behav. 2012 Mar;101(1):41-8
pubmed: 22130445
Neuron. 2012 Jun 21;74(6):1075-86
pubmed: 22726837
J Pharmacol Exp Ther. 1990 Mar;252(3):1370-7
pubmed: 2319472
Nature. 2013 Feb 14;494(7436):238-42
pubmed: 23354054
Neurosci Biobehav Rev. 2014 Jan;38:125-34
pubmed: 23928090
Front Syst Neurosci. 2013 Sep 18;7:50
pubmed: 24065893
Front Syst Neurosci. 2013 Dec 16;7:110
pubmed: 24379762
Neuroscience. 1989;29(3):503-37
pubmed: 2472578
J Comp Neurol. 1989 Nov 8;289(2):189-201
pubmed: 2478598
Exp Neurol. 2015 Mar;265:122-8
pubmed: 25597650
Mov Disord. 2015 Aug;30(9):1155-70
pubmed: 25772380
JAMA Psychiatry. 2015 May;72(5):490-9
pubmed: 25785435
Cell. 2015 Aug 13;162(4):712-25
pubmed: 26276628
Neuron. 2015 Sep 2;87(5):1063-77
pubmed: 26335648
J Neurosci. 2015 Dec 16;35(50):16340-51
pubmed: 26674861
Neuron. 2015 Dec 16;88(6):1121-1135
pubmed: 26687221
J Neurosci. 2016 Jan 27;36(4):1128-39
pubmed: 26818502
J Neurophysiol. 1989 May;61(5):900-17
pubmed: 2723733
Biol Psychiatry. 2016 Oct 1;80(7):509-21
pubmed: 27450032
PLoS Biol. 2016 Dec 6;14(12):e1002582
pubmed: 27923040
PLoS One. 2017 Mar 30;12(3):e0174790
pubmed: 28358895
Neuron. 2017 Aug 30;95(5):1171-1180.e7
pubmed: 28858619
J Neurosci. 2018 Feb 14;38(7):1699-1710
pubmed: 29330326
J Neurosci. 2018 Feb 21;38(8):1901-1914
pubmed: 29348192
eNeuro. 2018 Apr 19;5(2):
pubmed: 29766044
Cell. 2018 Jun 28;174(1):44-58.e17
pubmed: 29779950
Exp Brain Res. 1988;71(2):431-6
pubmed: 3169174
Behav Neural Biol. 1979 Oct;27(2):187-200
pubmed: 508216
Psychopharmacologia. 1970;16(4):305-12
pubmed: 5461437
Psychopharmacology (Berl). 1984;82(3):174-80
pubmed: 6144126
Neuropharmacology. 1981 Jan;20(1):29-37
pubmed: 6261181
Life Sci. 1981 Apr 6;28(14):1597-603
pubmed: 6264256
Brain. 1978 Mar;101(1):143-62
pubmed: 638722
Pharmacol Biochem Behav. 1984 Oct;21(4):501-6
pubmed: 6504948
Behav Neural Biol. 1984 Sep;42(1):52-60
pubmed: 6508693
Naunyn Schmiedebergs Arch Pharmacol. 1978 Apr;302(2):133-9
pubmed: 652059
Brain Res Bull. 1983 Sep;11(3):309-14
pubmed: 6640361
Prog Neurobiol. 1980;14(2-3):69-97
pubmed: 6999537
Brain Res. 1995 Apr 24;677(2):333-6
pubmed: 7552260
Psychopharmacology (Berl). 1994 Sep;116(1):65-72
pubmed: 7862932
Brain Res Bull. 1995;38(6):551-9
pubmed: 8590077
J Neurosci. 1997 Jun 1;17(11):4434-40
pubmed: 9151760
Eur J Pharmacol. 1976 Apr;36(2):423-9
pubmed: 945168
Brain Res. 1998 Mar 30;788(1-2):111-7
pubmed: 9554973

Auteurs

Dorin Yael (D)

The Leslie and Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, 52900, Israel.

Orel Tahary (O)

The Leslie and Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, 52900, Israel.

Boris Gurovich (B)

The Leslie and Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, 52900, Israel.

Katya Belelovsky (K)

The Leslie and Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, 52900, Israel.

Izhar Bar-Gad (I)

The Leslie and Susan Goldschmied (Gonda) Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat-Gan, 52900, Israel izhar.bar-gad@biu.ac.il.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH